| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/14/2006 | CA2598503A1 New ophthalmologic compositions and their method of use |
| 09/14/2006 | CA2598353A1 Non-fibrous transdermal therapeutic system and method for its production |
| 09/14/2006 | CA2598249A1 Treatment of hyperproliferative diseases with anthraquinones |
| 09/14/2006 | CA2598072A1 Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
| 09/14/2006 | CA2597255A1 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/14/2006 | CA2597213A1 Compositions and methods for treating or preventing flaviviridae infections |
| 09/14/2006 | CA2596830A1 Pyrrolopyrimidines useful as inhibitors of protein kinase |
| 09/14/2006 | CA2596031A1 Injectable preparations of diclofenic and its pharmaceutically acceptable salts |
| 09/14/2006 | CA2595033A1 Gastroresistant pharmaceutical formulations containing rifaximin |
| 09/13/2006 | EP1700868A2 A method for removing an antibody from blood or plasma |
| 09/13/2006 | EP1700858A1 Salts of a quinuclidine derivative as muscarinic M3 receptor antagonists |
| 09/13/2006 | EP1700856A1 Thiazole derivative |
| 09/13/2006 | EP1700851A1 Crystalline citalopram diol intermediate alkali |
| 09/13/2006 | EP1700850A1 Novel phenylalanine derivative |
| 09/13/2006 | EP1700617A1 Composition for activating the hair follicules and use thereof |
| 09/13/2006 | EP1700605A2 Lyophilized methionine-containing protein preparations stabilized over long time |
| 09/13/2006 | EP1700603A2 Immunostimulatory nucleic acids |
| 09/13/2006 | EP1700602A1 Pharmaceutical composition for use in hormone replacement therapy |
| 09/13/2006 | EP1700601A2 Use of dextromethorphan and an oxidase inhibitor for weaning patients from narcotics and anti-despressants |
| 09/13/2006 | EP1700600A1 Fulvic acid and its use in the treatment of inflammation |
| 09/13/2006 | EP1700599A1 Fulvic acid and its use in the treatment of candida infections |
| 09/13/2006 | EP1700598A1 Anti-proliferative combination therapy comprising satraplatin or JM118 and docetaxel |
| 09/13/2006 | EP1700597A1 Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application |
| 09/13/2006 | EP1700596A1 Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
| 09/13/2006 | EP1700159A1 Digital still camera with audio decoding and coding, a printable audio format, and method |
| 09/13/2006 | EP1700122A2 Immunoassays, haptens, immunogens and antibodies for anti-hiv therapeutics |
| 09/13/2006 | EP1699925A1 Il-23 and its receptor; related reagents and methods |
| 09/13/2006 | EP1699924A2 Antisense compounds targeted to connexins and methods of use thereof |
| 09/13/2006 | EP1699844A1 Hyperbranched polymers |
| 09/13/2006 | EP1699819A2 Treatment of coronary or peripheral ischemia |
| 09/13/2006 | EP1699812A2 Inhibitors of methionine aminopeptidase-2 and uses thereof |
| 09/13/2006 | EP1699808A1 Bifunctional macrolide heterocyclic compounds and methods of making and using the same |
| 09/13/2006 | EP1699806A1 Glycosaminoglycan (gag) mimetics |
| 09/13/2006 | EP1699803A1 Novel compounds |
| 09/13/2006 | EP1699802A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699801A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699800A2 Bicyclic heterocyclic p-38 kinase inhibitors |
| 09/13/2006 | EP1699799A1 Control of parasites in animals by the use of imidazo [1,2-b]pyridazine derivatives |
| 09/13/2006 | EP1699798A2 Di-substituted pyrrolotriazine compounds |
| 09/13/2006 | EP1699797A1 Pyrrolotriazine compounds as kinase inhibitors |
| 09/13/2006 | EP1699796A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 09/13/2006 | EP1699795A1 Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalklymine]-pyrimido[1,2a]pyrimidin-6-one derivatives |
| 09/13/2006 | EP1699793A1 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level |
| 09/13/2006 | EP1699792A1 Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds |
| 09/13/2006 | EP1699791A1 Novel tricyclic spiroderivatives as modulators of chemokine receptor activity |
| 09/13/2006 | EP1699789A2 Synthesis of a polymorph of 4-amino-5-chloro-2-methoxy-n-(1-azabicyclo[3.3.1]non-4-yl)benzamide hydrochloride hydrate |
| 09/13/2006 | EP1699788A2 Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
| 09/13/2006 | EP1699787A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699786A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699785A2 3-quinuclidinyl amino-substituted biaryl derivatives |
| 09/13/2006 | EP1699783A1 Opioid receptor antagonists |
| 09/13/2006 | EP1699782A1 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
| 09/13/2006 | EP1699781A1 1-acetic acid-indole, -indazole and -benzimidazole derivatives useful for the treatment of respiratory disorders |
| 09/13/2006 | EP1699780A1 Novel quinoline derivatives |
| 09/13/2006 | EP1699779A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof |
| 09/13/2006 | EP1699778A1 (4-phenylpiperazin-1-yl)acylpiperidine derivatives, preparation thereof and application of same in therapeutics |
| 09/13/2006 | EP1699777A1 Dipeptidyl peptidase inhibitors |
| 09/13/2006 | EP1699766A1 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors |
| 09/13/2006 | EP1699762A1 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension |
| 09/13/2006 | EP1699761A1 Cb1 modulator compounds |
| 09/13/2006 | EP1699760A2 Anti-hypercholesterolemic compounds |
| 09/13/2006 | EP1699759A1 Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| 09/13/2006 | EP1699758A1 Diphenylazetidinone derivates processing cholesterol absorption inhibitory activity |
| 09/13/2006 | EP1699529A1 Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent |
| 09/13/2006 | EP1699500A1 Crosslinked hyaluronic acid compositions for tissue augmentation |
| 09/13/2006 | EP1699490A2 Medical lipolysis of fat accumulations |
| 09/13/2006 | EP1699489A2 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 09/13/2006 | EP1699488A2 Therapeutic combination for cognition enhancement and psychotic disorders |
| 09/13/2006 | EP1699477A2 Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
| 09/13/2006 | EP1699473A2 Solvent for biogenic active pharmaceutical ingredients |
| 09/13/2006 | EP1699468A1 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis |
| 09/13/2006 | EP1699467A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors |
| 09/13/2006 | EP1699466A2 New compounds useful as metal chelators |
| 09/13/2006 | EP1699465A1 Treatment |
| 09/13/2006 | EP1699464A1 Menstrual cycle control and improvement of conception rates in females |
| 09/13/2006 | EP1699463A1 Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and zizyphi fructus extract |
| 09/13/2006 | EP1699462A1 Reduction of toxicity of multi-targeting antifolates |
| 09/13/2006 | EP1699461A1 Treatment of hepatic fibrosis with imatinib mesylate |
| 09/13/2006 | EP1699460A2 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
| 09/13/2006 | EP1699459A1 Method for treatment of multiple sclerosis |
| 09/13/2006 | EP1699458A1 Pharmaceutical composition |
| 09/13/2006 | EP1699457A1 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing |
| 09/13/2006 | EP1699456A1 Use of macrolides for treating or preventing airflow obstruction |
| 09/13/2006 | EP1699455A1 Heterocyclic aspartyl protease inhibitors |
| 09/13/2006 | EP1699454A1 Pyrazole derivatives and use thereof as orexin receptor antagonists |
| 09/13/2006 | EP1699453A1 Cyclic guanidines, compositions containing such compounds and methods of use |
| 09/13/2006 | EP1699452A2 Use of statins for the treatment of metabolic syndrome |
| 09/13/2006 | EP1699451A2 Use of at least one effector of glutathione metabolism, together with alpha-liponic acid for the treatment of lung deseases |
| 09/13/2006 | EP1699450A2 Co-administration of dopamine-receptor binding compounds |
| 09/13/2006 | EP1699449A1 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| 09/13/2006 | EP1699448A2 Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid |
| 09/13/2006 | EP1699447A1 Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite |
| 09/13/2006 | EP1699446A1 Compositions and methods for treating hepatitis c virus (hcv) infection |
| 09/13/2006 | EP1699444A2 Means for inhibiting viral replication by regulation of protein folding |
| 09/13/2006 | EP1699443A2 Pharmaceutical formulations of bisphosphonates |
| 09/13/2006 | EP1699442A2 Enteric coated aliphatic amine polymer bile acid sequestrants |
| 09/13/2006 | EP1699440A1 Method for the production of an administration form which is secured against misuse |
| 09/13/2006 | EP1699439A2 Controlled-release pharmaceutical formulation |
| 09/13/2006 | EP1699438A2 Pharmaceutical preparation containing gabapentin |
| 09/13/2006 | EP1699436A2 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |